discovered that the gene signatures of CD8+ TRM cells in triple-negative breast cancer patients are significantly associated with their response to pembrolizumab, highlighting the critical role of these cells in maintaining long-term anti-tumor immunity and their potential as targets for breast cancer vaccines (69). The gene discussed is CD8A; the disease is breast cancer.